Mr Turnbull was appointed Executive Chairman in November 2006, and has extensive experience in a senior capacity in both public and private companies. First appointed to a fully listed plc board when he was 29 he has enjoyed a 30 year career as a CEO and senior executive. For 15 years he was CEO of Texas Group Plc where he was active in numerous acquisitions and flotations. This Manchester based venture capital company was instrumental in the formation and development of Source BioScience in the years prior to its flotation. He is Non-Executive Chairman of CBG Group Plc, the Aim quoted insurance broker and financial services company and Non-Executive Chairman of Texas Holdings Ltd.

Dr Ash is the Managing Director of Source BioScience plc, taking up the position in February 2007, having previously been the group’s Chief Financial Officer. A Chartered Accountant with a PhD in Mycology from Sheffield University, Nick has reshaped the group by refocusing activities in the UK, playing a key role in the disposal of the group’s Dubai operations in 2006. Nick has also overseen the acquisition of Geneservice Limited (July 2007) and Autogen Bioclear UK Limited (March 2008) thereby acquiring the technologies and expertise necessary for the group's current and planned range of services. He worked at Eastern Airways and spent nine years with KPMG before joining Source BioScience in 2005.

Prior to joining Source BioScience, Dr Weaver was the Chief Executive of Geneservice Limited, a genomics-based products and contract research service business, formed from the UK Medical Research Council’s human genome project. From 1998 he was Director of Technology Development for Incyte Genomics in Cambridge, where his team developed high-throughput methods for mutation detection and genotyping in Mouse and Human. From 1996 he was Head of Biology at Hexagen Ltd. Prior to this he was a post-doctoral research fellow at the University of Cambridge and MRC Lab of Molecular Biology. He received his PhD in Oncology from the University of Wisconsin Medical School in 1990. Dr Weaver is also on the scientific advisory board of Pronostics Ltd and the Genetics Society.

Dr Foden is a Non-Executive Director for a number of public and private companies including Vectura plc, Piramed Limited and CellCentric Ltd. She also sits on the Boards of two seed funds, The Rainbow Seed Fund and the University Challenge Seed Fund, Cascade Limited. On behalf of the EIF, Dr Foden sits on a drug discovery Investment Committee in Leuven and she is a Trustee of the Institute of Cancer Research. Prior to 2003, Dr Foden spent time in venture capital with Merlin Biosciences, and in technology transfer with Cancer Research Campaign Technology Limited (now CRT) and Celltech. Dr Foden holds an MA and DPhil in Biochemistry from the University of Oxford.

Mr Slinger joined the Board as a Non-Executive Director in January 2005. Until June 2004 Mr Slinger had worked for 34 years at the Royal Bank of Scotland plc, most recently as a Director of Corporate Banking. Over the last ten years he had specific responsibilities for corporate clients active within the London, New York and Amsterdam exchanges, gaining broad experience in public listings, placements and general corporate activity in acquisitions and disposals. Mr Slinger is an Associate of The Chartered Institute of Bankers and also Deputy Chairman of CBG Group plc, which is an insurance company quoted on the Alternative Investment Market of the London Stock Exchange.